May.20.2021
R & D
Four-Year Data from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
This material is intended to notify the press release issued on May19 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
Please click https://www.bms.com/media/press-releases.html for the original press release.